At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 43 target
Drug / intervention
Anlotinib and Docetaxeldrug
Likely dose
Anlotinib and Docetaxel 12mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study to Evaluate the Effectiveness and Safety of Anlotinib Combined With Docetaxel in Progress After First Line Standard Cheomotherapy in Advanced Non-driver Mutation Non- Squamous Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Anlotinib and Docetaxel for Non-Squamous Non Small Cell Lung Cancer. Targeting 43 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedAug 2018
Primary CompletionDec 2024
Study CompletionJun 2025
TodayJul 2026
First PostedAug 24, 2018
Enrollment StartAug 1, 2018
Primary CompletionDec 31, 2024
Study CompletionJun 1, 2025
TodayJul 1, 2026
Enrollment to primary: 6.4 yearsPosted 7.9 years ago
Interventions
Anlotinib and Docetaxeldrug
Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)